The double face of Janus: a historical account of the emergence of bone marrow transplantation. by Scanlan, Camilla Louise & Kerridge, I
OPEN ACCESS
Jacobs Journal of Bone Marrow and Stem Cell Research
The Double Face of Janus: A Historical Account of the Emergence of Bone Marrow 
Transplantation
Camilla Scanlan*1, Ian Kerridge 1, 2
1 Centre for Values, Ethics & the Law in Medicine, University of Sydney NSW, Australia
2 Department of Hematology, Royal North Shore Hospital, St Leonards, NSW, Australia
Corresponding author: Dr. Camilla Scanlan, Centre for Values, Ethics & the Law in Medicine, University of Sydney NSW, 2006, 
Australia, Tel: 61(0)413 963 738; Email: Camilla.scanlan@sydney.edu.au
Received:     02-16-2016
Accepted:    02-24-2016
Published:   
Copyright:  © Camilla 2016
Perspective
Cite this article:  Scanlan C. The Double Face of Janus: A Historical Account of the Emergence of Bone Marrow Transplantation. J J Bone Stem Res. 2016, 2(1): 011.
AbstractHistory of modern blood and marrow transplantation (BMT) emerged, as is the case with most new biomedical interventions 
from sustained clinical and scientific research. But BMT also has a much darker antecedent – nuclear power and chemical 
warfare. 
It is important that we know the full story of the emergence of BMT for two reasons. The first is that it illustrates how 
accounts of the history of medicine in terms of heroes and beneficent progress are simplistic and often erroneous. The 
second is that it reminds us that biomedical knowledge may arise from human misery and may also cause it. 
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Introduction The history of bone marrow transplantation is a rich and 
interesting account. It has its beginnings around the time of World War II, and was founded in concerns about the biological 
consequences of atomic warfare [1]. As a result, much of the early research into the effects of exposure to ionizing radiation and the possibility of hematopoietic ‘rescue’ was conducted under the auspices of various Departments of Defense and was 
not published until many years later [2].  
Knowledge of the Effects of Ionizing Radiation During the 1940s and 50s Leon Jacobson [3], in a series of elegantly designed experiments conducted at the University of Chicago, described the sensitivity of the hematopoietic 
system to ionizing radiation. Jacobson demonstrated that 
mice exposed to radiation in doses sufficient to destroy the hematopoietic cells in the bone marrow, did not die when the spleen (the organ of hematopoiesis in the mouse) was shielded from the direct effects of radiation, suggesting that death following exposure to radiation was due, at least in part, 
to failure of the hematopoietic system. In subsequent studies, Jacobson and colleagues exposed another cohort of mice to total body irradiation (TBI), but followed this, in some of the mice, with an intraperitoneal injection of cells derived from 
the spleen. When those mice that had received the splenic cells survived, Jacobson concluded that these mice had essentially been ‘rescued from death’ (a term that continues to be used in the 21st century) by the re-establishment of hematopoiesis. 
The Importance of ‘likeness’ between Donor and 
Recipient Concurrent with this research, Lorenz and colleagues [4] had shown that guinea pigs exposed to lethal doses of 
radiotherapy could be kept alive if they were injected/infused 
with hematopoietic cells taken from the bone marrow of a 
genetically identical littermate. This research built upon the 
work of the Nobel Laureate Alexis Carrel in the early 1900s that showed that cells or organs transplanted from one individual (donor) to another (recipient), would be recognized by the recipient as being ‘foreign’ if the pair were not genetically 
identical – with graft rejection occurring following nonidentical transplantation but not after syngeneic transplantation (ie 
between monozygotic twins) [5,6]. (A process subsequently 
demonstrated by Doherty and Zinkernagel to be mediated by a dense clustering of genes associated with the major 
histocompatibility complex (MHC) [7].)
As the immune system and the immunobiology of transplantation became better understood, over the following decades increasing attention was devoted to the need to immunologically ‘match’ donors to recipients who were not 
genetically identical. While this led to some success – with 
many irradiated-then-infused allogeneic recipients remaining 
free of malignancy – many also developed severe diarrhea, 
weight loss, and skin lesions – a constellation of signs and symptoms that Balner and colleagues termed ‘secondary 
disease’, but which is now know as graft-versus-host disease (GvHD) [ 8]. This early research had therefore shown that hematopoietic tissue destroyed by irradiation, could be replaced and repopulated by infusing a suspension of hematopoietic cells 
derived from a healthy donor. The survival and proliferation of such grafts occurred, not as a consequence of a humoral response, as had been postulated by Jacobson [9], but as Ford 
et al identified [10] because [a] the infused cell suspension colonized the vacant spaces in the bone marrow of the 
recipient, taking over the role of producing blood cells and [b] the body, as a result of the irradiation, failed to recognize the infused cells as foreign, and destroy them by the elaboration 
of antibodies produced against them i.e. by an immunogenic 
response. 
From the start – this new knowledge was recognized as having implications not only for the military, (Ford was funded by the 
British Atomic Energy Research Establishment, and Jacobson 
by the USA’s Atomic Energy Commission) but in clinical 
settings – opening up the possibility of curing  patients with radiosensitive malignant disease, particularly hematological malignancies, by the purposeful destruction of their malignant cells with radiotherapy (and subsequently chemotherapy), 
followed by the infusion of healthy marrow cells.  
The First Successful Bone Marrow Transplant in 
Humans 
Although the American physician Robert A Good is often 
believed to have performed the first successful bone marrow 
transplant in 1968 [11] the first ‘successful’ bone marrow 
transplant had actually occurred almost a decade earlier. On 
October 15 1958, six persons were exposed to high doses of neutrons and gamma radiation during an accident at a nuclear 
research reactor at Vinca in former Yugoslavia (now known 
as Serbia and Montenegro). All six individuals were flown to the Hôpital Curie in Paris under the care of oncologist Georges 
Mathé. Initially they were treated for severe radiation sickness 
with transfusions of whole blood, packed red blood cells, 
concentrated platelets, γ-globulin, and antibiotics, but they did 
not show any signs of clinical improvement. On the 27th day after the accident, a suspension of human adult bone marrow 
cells was infused intravenously to five of the six patients (the man not transplanted having received a sub-lethal dose of 
radiation). Each transplanted patient’s condition improved, however one of the men died shortly thereafter as a result of 
radiation damage to the viscera. Four of the five transplanted 
victims survived [12,13]. Notwithstanding, whilst Mathé's 
BMTs likely contributed to the survival of the 5 workers 
Jacobs Publishers 3
Cite this article:  Scanlan C. The Double Face of Janus: A Historical Account of the Emergence of Bone Marrow Transplantation. J J Bone Stem Res. 2016, 2(1): 011.
who developed radiation sickness, until Good and his team successfully transplanted a 5-month old boy with Severe 
Combined Immunodeficiency (SCID) with bone marrow from his 8-year old sister, all of the more than 200 attempts to transplant bone marrow in humans had led to the death of the 
recipients [14]. 
Elsewhere in the United States, researchers were exploring the 
immunological basis of transplantation and graft rejection. E 
Donnall Thomas, in particular, was one of the first to recognize the impact of genetic match between donor and recipient on 
graft and recipient survival. Thomas, who was later to receive 
the Nobel Prize for Physiology and Medicine for his work, his wife Dottie and their team, began applying insights drawn from experiments on dogs to advancing unrelated donor BMT 
in human trials in the 1960s. (Prior to this all successful BMTs 
had been between genetically identical siblings.) [15] Finally, 
in 1969, after years of work on developing an understanding of, and the means of detecting the effects of immunological differences between donor and recipient (histocompatibility) by assays (tissue typing) and development of antibiotics that 
inhibit transplant infections, Thomas performed the first successful unrelated allogeneic bone marrow transplant 
in humans [16]. – work that was to form the basis for the expansion of BMT throughout the world and to the foundation 
of the Fred Hutchinson Cancer Research Centre in Seattle.The differences between the transplants performed by Mathé and Thomas are worthy of note because they illustrate how much had been achieved during the decade that separated 
their work. The transplants done by Mathé were performed under emergency conditions; exposure to radiation had been 
accidental and the doses were uncontrolled – being variously described as supra-lethal, lethal and sub-lethal; the donor and recipients had been matched on sex and major blood groups only; and the intention was to ‘rescue’ patients from the effects 
of an industrial radiation exposure [17]. In contrast, in Thomas’ patients the doses of radiation administered were controlled and calculated on body mass;  donors had been matched to recipients using tissue typing to the level of complexity as was 
known at the time; and the intention was cure an underlying 
hematological malignancy.  
Adjunct TherapyThe subsequent development of bone marrow transplantation as a clinical therapy owes much to the development of 
chemotherapy [18]. The use of chemotherapy (a term coined 
by the German chemist Paul Ehrlich) to treat cancer, rather 
than infection, was prompted by knowledge derived from 
experiences with chemical warfare and, more specifically, with 
the use of mustard gas in World War I. Initial studies done in 1943, but not published until much later [19], revealed that soldiers who had come into contact with mustard 
gas experienced high rates of bleeding (both internally 
and externally) and were highly susceptible to infections. Subsequent reports revealed that men exposed to mustard gas during World War II had bone marrow failure and that 
this was the cause of much of its toxicity. Drawing from these insights it was reasoned that if chemicals could affect normal hematopoietic cells then they might also affect rapidly growing 
malignant cells [20]. To test this hypothesis, nitrogen mustard was used to treat patients with lymphoma, often with some initial success, although remissions turned out to be brief and incomplete, leading many researchers to believe that cancer 
was not curable by drugs.  Progress in understanding the roles of both radiotherapy and chemotherapy in treating patients with various malignancies 
advanced significantly during the following decades. Early research conducted in  the 1960s [21-25] demonstrated that 
the ability of these agents to kill tumor cells was directly related to the doses given to the patient - the higher the dose, 
the better the ‘kill rate’ – leading to intensification of  radiation 
and/or chemotherapy doses in the hope that this may 
increase cure and reduce the likelihood of post-BMT relapse. While this strategy was, in many situations, successful, it also resulted in greater toxicity to normal tissue, in particular the gastrointestinal tract, the renal, hepatic, pulmonary, liver and cardiac systems, causing much of the mortality and morbidity 
associated with BMT [26]. More recently, a range of strategies have been pursued with 
the intention of reducing the toxic effects of radiation and/
or chemotherapy and optimising not only the likelihood of post-BMT survival but the quality of post-BMT survival. These strategies have included the use of ‘reduced intensity’ transplant conditioning protocols, increasingly sophisticated approaches to tissue-typing, better supportive care and the exploration of immunotherapy rather than pharmacotherapy 
to treat both malignancy and infection. Collectively, progress in 
these areas will likely increase the number of patients eligible 
for BMT and outcomes following BMT.
ConclusionBMT is now clearly established as standard treatment for a wide variety of life-threatening diseases affecting both children and adults and provides long-term disease free survival in up to 
80% of patients. While it is often tempting to read the scientific 
and clinical emergence of medical therapies, like BMT, as a story 
of inexorable and beneficent progress, of the brave triumph of medical science over disease, in fact medical advance is rarely 
so simple and often results from serendipitous findings or 
after long periods of fruitless or misguided study. And in some situations, such as with BMT, medical advance arises in the context of human misery or following the pursuit of science 
for militaristic purposes. While this does not invalidate or even 
sully the benefits that accrue from BMT it should give us pause 
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to acknowledge the capacity of science, and knowledge more 
generally, to reduce but also to cause suffering.
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